PharmaVoice 100: Page 2

  • A portrait of Carl Turner framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Carl Turner
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Carl Turner

    How Klick’s first-ever chief brand strategy officer is relying on collaboration to advance innovative strategies for clients and opportunities for people of color.

    By • Sept. 6, 2022
  • A portrait of Carol Lynch framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Carol Lynch
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Carol Lynch

    The chief business officer for Sandoz combines a shrewd business sense with a generous approach to leadership.

    By Alexandra Pecci • Sept. 6, 2022
  • A portrait of Charlene Stern framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Charlene Stern
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Charlene Stern

    How the chief lawyer of Editas Medicine is using a multi-lens approach to bolster the development of game-changing genomic medicines.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Chris Round framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Chris Round
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Chris Round

    The president of EMD Serono, the U.S. and Canadian healthcare business unit of Merck KGaA, Darmstadt, Germany, has the company firing on all cylinders for near- and long-term growth.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Dr. Cristian Massacesi framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Cristian Massacesi
    Image attribution tooltip
    Profile // PharmaVoice 100

    Innovators: Dr. Cristian Massacesi

    With the goal of redefining how medicines are made, the CMO and oncology CDO is transforming AstraZeneca’s oncology development.

    By • Sept. 6, 2022
  • A portrait of David Katz framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by David Katz
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: David Katz

    As the founder and chief scientific officer of Sparrow Pharmaceuticals, David Katz is breathing new life into drugs that have previously been shelved.

    By • Sept. 6, 2022
  • A portrait of Dawn Berry framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dawn Berry
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: Dawn Barry

    The co-founder and president of LunaPBC is seeking to eliminate the middlemen in drug development by connecting patients — and their real-world data — directly with researchers.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Dominique Demolle framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dominique Demolle
    Image attribution tooltip
    Profile // PharmaVoice 100

    Tech Wizards: Dominique Demolle

    How the CEO of Cognivia is revolutionizing drug development with psychonomics.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Dr. Judith Klimovsky framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Judith Klimovsky
    Image attribution tooltip
    Profile // PharmaVoice 100

    Innovators: Dr. Judith Klimovsky

    The executive vice president and chief business officer of Genmab is using decades of experience in oncology R&D to fuel advances in antibody-drug conjugates. 

    By • Sept. 6, 2022
  • A portrait of Dr. Jula Inrig framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Jula Inrig
    Image attribution tooltip
    Profile // PharmaVoice 100

    Innovators: Dr. Jula Inrig

    The longtime devotee to kidney disease research is using a novel trial design to advance treatments for rare conditions at Travere.

    By • Sept. 6, 2022
  • A portrait of Dr. Michael Hayden framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Michael Hayden
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Dr. Michael Hayden

    The CEO at Prilenia has an unwavering dedication to address the needs of HD patients and their families.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Dr. Pam Diamond framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Pam Diamond
    Image attribution tooltip
    Profile // PharmaVoice 100

    DE&I Champions: Dr. Pam Diamond

    The chief medical officer and co-founder of Curavit Clinical Research is bringing a new level of inclusiveness to clinical trials.

    By • Sept. 6, 2022
  • A portrait of Samantha Du framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Samantha Du
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: Samantha Du

    The CEO of Zai Lab is at the forefront of the movement to boost innovation in China’s biotech sector while delivering needed solutions to patients around the world.

    By • Sept. 6, 2022
  • A portrait of Dr. Edward Kaye framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Edward Kaye
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Dr. Edward Kaye

    The CEO behind the first genetic therapy for Duchenne muscular dystrophy is looking to extend his winning streak at Stoke.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Elisha Hughes framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Elisha Hughes
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Elisha Hughes

    The director of research biostatistics at Myriad Genetics is looking to stretch the boundaries of science and change how breast cancer is detected in diverse patient populations.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Fahti Khosrowshahi framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Fahti Khosrowshahi
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Fahti Khosrowshahi

    The president, CEO and founder of Ceek Women’s Health is on a mission to upend the OBGYN market.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Faraz Ali framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by NASDAQ
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Faraz Ali

    The CEO is leading Tenaya Therapeutics forward in ways that combine people-focused leadership, a strong dedication to patients and bold ideas for the future.

    By Alexandra Pecci • Sept. 6, 2022
  • A portrait of Frank Lee framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Frank Lee
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Frank Lee

    At Forma Therapeutics, the CEO and president is placing patients in leadership roles to weave patient centricity into the company’s business and development model.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Giacomo Chiesi framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Giacomo Chiesi
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Giacomo Chiesi

    For the head of Chiesi Global Rare Diseases, patient centricity is in his DNA.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Helen Sabzevari framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Helen Sabzevari
    Image attribution tooltip
    Profile // PharmaVoice 100

    Tech Wizards: Helen Sabzevari

    The CEO of Precigen is on a mission to develop next-generation gene and cell therapies for cancers, autoimmune disorders and more.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Dr. Helen Thackray framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Helen Thackray
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Dr. Helen Thackray

    The chief research and development officer at BioCryst Pharmaceuticals is leaning into decades of experience to advance a promising pipeline of rare disease products.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Henrietta Ukwu framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Henrietta Ukwu
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Dr. Henrietta Ukwu

    Novavax’s regulatory head helped the company pull off its first approvals with the FDA and the EMA — but her accomplishments in pharma run deep.

    By • Sept. 6, 2022
  • A portrait of Houda Hachad framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Houda Hachad
    Image attribution tooltip
    Profile // PharmaVoice 100

    Tech Wizards: Houda Hachad

    This inventor and 'entrepreneurial scientist' is developing new technologies to manage data and use insights from genomic testing at AccessDx Laboratory.

    By Alexandra Pecci • Sept. 6, 2022
  • A portrait of Dr. Ian Walters framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Ian Walters
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Dr. Ian Walters

    How the CEO of Portage Biotech is steering cancer R&D in a new direction by advancing diverse drug platforms.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Dr. Jane Barlow framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Jane Barlow
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Dr. Jane Barlow

    The executive vice president and chief clinical officer of Real Endpoints is boosting patient access to innovative therapies through value-based payer agreements.

    By • Sept. 6, 2022